Boston runs on science. MIT, Harvard and the city's hospitals spin out a steady stream of biotech, robotics and AI startups. That's why many Boston investors build companies, not just fund them. Below are 24 venture capital firms in Boston that invested in 2025 or 2026, grouped by what they back.

The top venture capital firms in Boston include General Catalyst, Battery Ventures and Bain Capital Ventures in tech. In biotech, look at Third Rock Ventures, Atlas Venture and Flagship Pioneering. For seed rounds, try Pillar VC, Glasswing Ventures and NextView Ventures. Every firm on our list invested in 2025 or 2026. Start with your sector.
- Massachusetts startups raised $16.6B in venture capital in 2025, PitchBook-NVCA data show.
- Biotech is a Boston speciality, and many of its investors start companies themselves.
- Boston firms lead many seed and Series A rounds. Funds from elsewhere led several of the biggest recent rounds.
- Seven firms on our list don't publish a fund size, so their recent deals tell you more.
Which venture capital firms in Boston are most active in 2026?
We picked firms that led or joined a round, or raised a fund, in 2025 or 2026. All 24 are based in Boston or Cambridge. We left out firms that have stopped investing, like OpenView. The table gives each firm's stages, its published fund or cheque size, and a recent deal we could check.
Venture capital firms in Boston: base, stages, size and a recent deal.
Sources: each firm's own website or a deal report, opened in November 2026 and linked in each row. A cheque size appears only where the firm publishes one; otherwise we give a fund size, or "not published". "Joined" means the firm invested but didn't lead. MPM BioImpact founded K2 Therapeutics and funded its seed alone.
For more names, here are Boston funds from our free investor database. Open any card for the fund's full profile.
- AI & Deep Tech
- Advertising & Marketing
- +34
- Seed
- Series A
- +5
- $500K-$1M
- $1M-$3M
- +2
- AI & Deep Tech
- Advertising & Marketing
- +31
- Seed
- Series A
- +3
- $100K-$500K
- $500K-$1M
- +3
- AI & Deep Tech
- Advertising & Marketing
- +29
- Seed
- Series A
- +3
- AI & Deep Tech
- Biotech
- +7
- Seed
- Series A
- +3
- $0-$100K
- $100K-$500K
- +3
- AI & Deep Tech
- Advertising & Marketing
- +19
- Seed
- Series A
- +3
- $1M-$3M
- $3M-$10M
- AI & Deep Tech
- Advertising & Marketing
- +33
- Seed
- Series A
- +3
- $500K-$1M
- $1M-$3M
- +2
- AI & Deep Tech
- Advertising & Marketing
- +32
- Seed
- Series A
- +3
- $0-$100K
- $100K-$500K
- +3
- AI & Deep Tech
- Advertising & Marketing
- +27
- Pre-Seed
- Seed
- +2
- AI & Deep Tech
- Advertising & Marketing
- +22
- Pre-Seed
- Seed
- +2
- AI & Deep Tech
- Advertising & Marketing
- +27
- Seed
- Pre-Seed
- +1
- $1M-$3M
- AI & Deep Tech
- Advertising & Marketing
- +22
- Seed
- Series A
- +4
- Legal & Professional services
- AI & Deep Tech
- +6
- Pre-Seed
- Seed
- +4
- $500K-$1M
- $1M-$3M
- +1
- AI & Deep Tech
- Advertising & Marketing
- +33
- Seed
- Series A
- +3
- $10M-$50M
- AI & Deep Tech
- Advertising & Marketing
- +32
- Pre-Seed
- Seed
- +4
- $3M-$10M
- Over $50M
- +1
- AI & Deep Tech
- Advertising & Marketing
- +26
- Series A
- Series C+
- +4
- Over $50M
- $10M-$50M
- AI & Deep Tech
- Advertising & Marketing
- +32
- Series A
- Series B
- +2
- $3M-$10M
- Over $50M
- +1
- AI & Deep Tech
- Advertising & Marketing
- +25
- Seed
- Series A
- +2
- $3M-$10M
- Over $50M
- +1
- AI & Deep Tech
- Advertising & Marketing
- +32
- Seed
- Series A
- +2
- $3M-$10M
- $10M-$50M
- Software & Apps
- AI & Deep Tech
- +5
- Series B
- Series C+
- +2
- $3M-$10M
- Over $50M
- +1
- AI & Deep Tech
- Advertising & Marketing
- +30
- Series A
- Series B
- +2

Which Boston VC firms back biotech and life sciences?
Third Rock Ventures, Atlas Venture, Flagship Pioneering, Polaris Partners, MPM BioImpact and Longwood Fund all start biotech companies themselves. F-Prime Capital also backs healthtech. These firms often create a company, hire its team and fund its first rounds. So expect a hands-on partner, not just a cheque.
Third Rock Ventures
Third Rock Ventures creates biotech companies and builds their teams. In December 2025 it co-led the Series A of Syremis Therapeutics (Globes). Syremis develops medicines for schizophrenia and other mental health conditions.
Atlas Venture
Atlas Venture starts biotech companies with seed money, then co-leads their Series A. Its newest fund has $450M (Atlas Venture). In June 2026 it co-led the launch round of Cambridge-based Ethyreal Bio, which treats thyroid eye disease.
Flagship Pioneering
Flagship Pioneering invents its own platform companies, then funds and staffs them. In April 2026 it launched Serif Biomedicines with a $50M commitment (Flagship Pioneering). Serif is turning modified DNA into a new class of medicines.
Polaris Partners
Polaris Partners backs biotech and healthcare companies, and incubates some itself. In October 2025 it co-led the Series A of Zag Bio, a company it incubated (Zag Bio). Zag Bio is a Cambridge startup working on autoimmune disease. Polaris is now raising its eleventh fund.
F-Prime Capital
F-Prime Capital invests in life sciences, healthtech and technology. It has offices in Cambridge, London and San Francisco. In October 2026 it led AblePay Health's $20M Series A (PR Newswire). AblePay helps patients manage what they pay out of pocket.
MPM BioImpact
MPM BioImpact founds biotech companies and runs venture, impact and public equity funds. In August 2026 it put $50M into the seed round of K2 Therapeutics, a company it founded (GlobeNewswire). K2 looks for promising drug candidates around the world.
Longwood Fund
Longwood Fund starts biotech companies and keeps backing them as they grow. Its office is in Boston's Prudential Tower. In January 2026 it joined Mediar Therapeutics' Series B as a new investor (ICG). Mediar is developing drugs to halt fibrosis.
For more health investors, see our guides to VC investing in life sciences and venture capital firms investing in healthcare.
Which Boston VCs back deep tech and climate?
The Engine, Material Impact, Clean Energy Ventures, Pillar VC and Safar Partners back hard tech: new materials, energy, robotics and fusion. They make longer bets than software funds, and they expect a strong technical team. Three of them raised funds of $175M or more since 2024. Most write the first institutional cheque.
The Engine
The Engine backs what it calls Tough Tech: founders turning hard science into products. Its newest fund has $400M for climate tech (Boston Globe). In March 2026 it led the seed round of Axiomatic AI, a Cambridge startup building verified AI for engineers.
Material Impact
Material Impact builds deep tech companies around new materials. It aims to be the first money in. In July 2026 it joined the Series A of Oxipital AI, based in Bedford, Massachusetts (PR Newswire). Oxipital makes AI vision software for food factories.
Clean Energy Ventures
Clean Energy Ventures funds early-stage climate technology. Its second fund closed at $305M (Clean Energy Ventures). In September 2026 it co-led Branch Energy's Series B. Branch supplies fast power for AI data centres.
Pillar VC
Pillar VC writes pre-seed and seed cheques for technical founders. Its fourth fund has $175M (Pillar VC). In September 2026 it co-led the seed round of G5 Labs, a Boston spinout of MIT's computer science and AI lab.
Safar Partners
Safar Partners invests in technology companies from seed to growth stage. Its portfolio includes the fusion developer Commonwealth Fusion Systems (Safar Partners). In February 2026 it led the seed round of GelMEDIX, which is developing therapies to restore vision.
For more, see our lists of deep tech venture capital firms and energy venture capital firms.
Which Boston VCs back software, fintech and AI?
General Catalyst, Battery Ventures and Bain Capital Ventures run billion-dollar funds and invest at many stages. Early AI and software startups get backing from .406 Ventures, Glasswing Ventures and Flybridge. Accomplice was an early backer of DraftKings and WHOOP. Even the biggest firms here lead seed rounds, so a first-time founder can pitch them too.
General Catalyst
General Catalyst invests from seed to growth equity. Its twelfth fund raised about $8B (General Catalyst). In March 2026 it co-led the Series B of Cloaked, which makes consumer privacy tools.
Battery Ventures
Battery Ventures invests in tech companies at every stage, from early rounds to buyouts. Its fifteenth fund closed at $3.25B (Battery Ventures). It also co-led the seed round of G5 Labs with Pillar VC.
Bain Capital Ventures
Bain Capital Ventures incubates ideas, leads seed rounds and backs growth companies. Its new $1.6B fund mainly targets seed to Series B (TechCrunch). In September 2026 it led the seed round of Corridor.
.406 Ventures
Boston's .406 Ventures backs early-stage healthcare, data and AI, and cybersecurity companies. It has raised over $1.3B across its funds (.406 Ventures). In September 2026 it led Teal Health's Series A. Teal makes an at-home cervical cancer screening test.
Glasswing Ventures
Glasswing Ventures aims to be the first investor in AI-native and frontier tech startups. Its third fund closed with over $200M (Glasswing Ventures). In June 2026 it led the seed round of Boston-based Enlaye.
Flybridge
Flybridge backs seed-stage AI companies from offices in New York and Boston. It leads or co-leads seed rounds with cheques of up to $3M (Flybridge). In January 2026 it led a round for Limy, which builds tools for AI agents on the web.
Accomplice
Accomplice calls itself a venture firm and a contemporary family office. It was an early backer of DraftKings, Hopper and WHOOP (Accomplice). In March 2026 it joined WHOOP's Series G.
For more, see our lists of AI venture capital firms and fintech venture capital firms.
Where do you find seed funds and angel investors in Boston?
NextView Ventures, Founder Collective and Underscore VC lead pre-seed and seed rounds. Pillar VC and Glasswing Ventures, above, do too. For smaller cheques, try the angel groups Launchpad Venture Group and Boston Harbor Angels. Have a working product, or strong science, before you pitch them.
NextView Ventures
NextView Ventures is a Boston seed firm that leads rounds before product-market fit. Its sixth fund is raising toward $135M (Boston Business Journal). In September 2026 it co-led Fambot's pre-seed round.
Founder Collective
Founder Collective is a seed and pre-seed fund with offices in Cambridge and New York (Founder Collective). In August 2026 it joined the seed round of Reservoir, which makes efficient water heaters.
Underscore VC
Underscore VC backs founders who apply AI to real-world problems, at pre-seed and seed (Underscore VC). In April 2026 it co-led Gander Robotics' pre-seed round. Gander, an MIT startup, builds underwater drones for finding people lost at sea.
Launchpad Venture Group
Launchpad Venture Group is a network of angels backing New England startups. Its members have invested over $125M in startups (Launchpad Venture Group). In January 2026 they joined ClearCut Surgical's seed round.
Boston Harbor Angels
Boston Harbor Angels is an angel group founded in 2004. Its members back early companies in life sciences, IT and other fields (Boston Harbor Angels). In February 2026 it joined GelMEDIX's seed round.
Raising online too? See our lists of seed stage investors and angel investing platforms.
How much venture capital do Boston startups raise?
Massachusetts startups raised $16.6B in venture capital in 2025, PitchBook-NVCA data show. The first half of 2026 ran about 30% ahead of the year before. AI, biotech and health companies raised many of the biggest rounds. Local firms lead plenty of early rounds, while funds from elsewhere led several of the largest.
Massachusetts venture capital, 2024 to mid-2026.
Sources: Boston Globe, citing the PitchBook-NVCA Venture Monitor: 15 January 2025 (row 1), 15 January 2026 and 9 July 2026 (rows 2–3).
The biggest rounds show who leads in Boston. Here are six from the past year, with their lead investors.
Boston's big 2025–26 rounds, and who led them.
Sources: company announcements for Commonwealth Fusion Systems, Kailera and WHOOP; Variety (Suno); Crunchbase News (Cloaked); Boston Globe (Blitzy).
Only two of those six had a Boston-area lead: Bain Capital on Kailera and General Catalyst on Cloaked. Local funds lead more often at earlier stages, like Atlas Venture on Ethyreal Bio's launch round. So plan your raise in layers. Boston investors bring the first cheques and the science network. National funds often bring the biggest leads.
Say you run a fictional Cambridge robotics startup raising a $3M seed. Pitch the seed funds above for a lead, and the deep tech funds in the same weeks. Add an angel group for smaller cheques. If no local fund leads, a national seed fund can. Our seed round benchmarks show what's normal for the round.

Boston investors, or funds from outside?
Start with Boston investors if…
- You're raising pre-seed or seed
- Your company came out of MIT, Harvard or a Boston hospital
- You're building biotech, medtech or hard tech
- Your team and first customers are near Boston
- You want an investor who helps build the company
Add funds from outside Boston if…
- You're raising a large Series B or later
- Most of your customers are on the West Coast or abroad
- You need a specialist lead the city lacks
- Local funds already back your rivals
- You want a well-known lead for the next round
How do you pitch Boston venture capital firms?
Lead with the science or the technical edge, then show who will pay for it. Boston investors read the data closely. In our work, 7 of 10 investor no-votes trace back to the story and the materials, not the product. So make your deck clear to a partner from outside your field.

- Pick investors by sector first — biotech, deep tech and software funds want different proof.
- Bring proof from a lab, a hospital or a pilot — Boston investors want evidence, not promises.
- Get introduced by a founder they backed — the table's recent deals show who those founders are.
- Line up an outside lead early — for big rounds, national funds often lead.
- Meet every fund in the same few weeks — then you can compare offers side by side.
Science-heavy companies have to win over investors who aren't scientists. Waveup prepared the investor materials for a clinical-stage oncology biotech's $20M Phase 2b raise. A 60-page research dump became a deck of under 25 pages that private investors could follow. Read the case.
Our fundraising team builds that kind of investment case: the deck, the financial model and the list of investors to target. Since 2014 we've built the decks, models, CIMs and valuations behind $3B+ raised for 600+ startups.